Zydus under three observations from FDA
Indian-based pharma company Zydus Lifesciences just got hit with a triple whammy by the U.S. FDA.
FDA Warning | 26/04/2022 | By Sudeep Soparkar | 625
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy